Y mAbs Therapeutics Asset Resilience Ratio
Y mAbs Therapeutics asset resilience ratio. Y mAbs Therapeutics (YMAB) has an Asset Resilience Ratio of 0.02% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Y mAbs Therapeutics liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Y mAbs Therapeutics (2016–2017)
Asset resilience ratio of Y mAbs Therapeutics from 2016 to 2017. This chart shows how Y mAbs Therapeutics's Asset Resilience Ratio has changed over time. Read Y mAbs Therapeutics debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Y mAbs Therapeutics's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see YMAB asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $31.00K | 0.02% |
| Total Liquid Assets | $31.00K | 0.02% |
Asset Resilience Insights
- Limited Liquidity: Y mAbs Therapeutics maintains only 0.02% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Y mAbs Therapeutics Industry Peers by Asset Resilience Ratio
Compare Y mAbs Therapeutics's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Y mAbs Therapeutics Asset Resilience Ratio by Year (2016–2017)
Y mAbs Therapeutics asset resilience ratio by year from 2016 to 2017. The table below shows the annual Asset Resilience Ratio data for Y mAbs Therapeutics.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 0.03% | $32.00K | $92.13 Million | -0.13pp |
| 2016-12-31 | 0.16% | $28.00K | $17.26 Million | -- |
About Y mAbs Therapeutics
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-ri… Read more